BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bermea RS, Sharma N, Cohen K, Liarski VM. Use of Eculizumab in Atypical Hemolytic Uremic Syndrome, Complicating Systemic Lupus Erythematosus. J Clin Rheumatol 2016;22:320-3. [PMID: 27556240 DOI: 10.1097/RHU.0000000000000423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Wright RD, Bannerman F, Beresford MW, Oni L. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 2020;21:245. [PMID: 32605540 DOI: 10.1186/s12882-020-01888-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
2 Fernandez-ruiz R, Belmont HM. The role of anti-complement therapy in lupus nephritis. Translational Research 2022. [DOI: 10.1016/j.trsl.2022.02.001] [Reference Citation Analysis]
3 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
4 de Holanda MI, Pôrto LC, Wagner T, Christiani LF, Palma LMP. Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review. Clin Rheumatol 2017;36:2859-67. [PMID: 28905254 DOI: 10.1007/s10067-017-3823-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]